Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets

Table 2

Summary of clinical trials in anti-CD38 antibody in relapse/refractory MM.

References		Phase	Regimen	ORR (%)	PFS (mo)	OS
Lokhorst et al. [28]	GEN501	1/2	Dara monotherapy	36%	5.6 mo	1 yr 77%
Lonial et al. [29]	SIRIUS	2	Dara monotherapy	17%	3.7 mo	1 yr 65%
Spencer et al. [32]	CASTOR	3	Bd ± Dara	83% vs 63%	1.5 yr 48% vs 8%	NA
Palumbo et al. [31]	CASTOR	3	Bd ± Dara	83% vs 63%	1 yr 61% vs 27%	NA
Dimopoulos et al. [33]	POLLUX	3	Rd ± Dara	93% vs 76%	1 yr 83% vs 60%	NA
Dimopoulos et al. [34]	POLLUX		Rd ± Dara	93% vs76%	2 yr 68% vs 41%	NA
Chari et al. [35]	EQULLEUS	1b	Pd ± Dara	60%	1 yr 42%	1 yr 89%

MM, multiple myeloma; Dara; daratumumab, Rd, lenalidomide plus dexamethasone; Bd, bortezomib plus dexamethasone; Pd, pomalidomide plus dexamethasone; NA, not available; MTD, maximum tolerated dose.